Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02410512 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Safety and Pharmacokinetics of MOXR0916 and Atezolizumab (Also Known as MPDL3280A or Anti-PD-L1) in Participants With Locally Advanced or Metastatic Solid Tumors
A Phase 1 study of Neoplasms, sponsored by Genentech.
- Completed
- Registry status
- Phase 1
- Development phase
- 610
- Enrollment target
- 20
- Study locations
NCT02410512: Completed Phase 1 study of Neoplasms, sponsored by Genentech.
NCT02410512 is a Phase 1 study of Neoplasms that has completed, run by Genentech. The registered enrollment target is 610 participants, below the 1,617-participant average among 158 other Neoplasms trials with a reported enrollment target (62% lower). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02410512, a Phase 1 study of Neoplasms, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 610 participants
- Enrollment target
- 20
- Study locations
Study Summary
This Phase Ib, open-label, dose-escalation study will evaluate the safety, tolerability, and pharmacokinetics of the combination of MOXR0916 and atezolizumab in participants with locally advanced, recurrent, or metastatic incurable solid malignancy that has progressed after available standard therapy; or for which standard therapy has proven to be ineffective or intolerable or is considered inappropriate; or for which a clinical trial of an investigational agent is a recognized standard of care. Participants will be enrolled in two stages: a dose-escalation stage and an expansion stage.
Conditions Studied
Interventions
- DRUG Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 [PD-L1] antibody
- DRUG MOXR0916, a humanized agonist anti-OX40 monoclonal antibody
Study Locations (20)
Other
- Institut Jules Bordet - Anderlecht
- UZ Gent - Ghent
- Sint Augustinus Wilrijk - Wilrijk
- Gustave Roussy - Villejuif
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
- Dana Farber Can Ins - Boston
Victoria
- Austin Hospital - Heidelberg
- Peter Maccallum Cancer Centre - Melbourne
Arizona
- HonorHealth Research Institute - Bisgrove - Scottsdale
Colorado
- University of Colorado - Aurora
Connecticut
- Yale School of Medicine - New Haven
District of Columbia
- Georgetown University Medical Center Lombardi Cancer Center - Washington D.C.
Illinois
- University Of Chicago Medical Center; Section Of Hematology/Oncology - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 610 participants |
| Start Date | 2015-04-24 |
| Est. Completion | 2019-11-22 |
| Phase | Phase 1 |
What the finished NCT02410512 record still lists
NCT02410512 is an interventional study that assigns participants to a tested intervention. The registered 610 participants enrollment target is mid-sized for trials with a published cap, below the 1,617-participant average among 158 other Neoplasms trials with a reported enrollment target (62% lower).
The record links to 1 condition, with Neoplasms appearing as the primary indexed condition, and to 2 interventions - of which Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 [PD-L1] antibody is the first listed.
NCT02410512 names 20 study sites across 15 states, led by Other, Massachusetts, Victoria.
Frequently Asked Questions
What is clinical trial NCT02410512 about?
NCT02410512 is a clinical study titled "A Study to Assess the Safety and Pharmacokinetics of MOXR0916 and Atezolizumab (Also Known as MPDL3280A or Anti-PD-L1) in Participants With Locally Advanced or Metastatic Solid Tumors". This Phase Ib, open-label, dose-escalation study will evaluate the safety, tolerability, and pharmacokinetics of the combination of MOXR0916 and atezolizumab in participants with locally advanced, recurrent, or metastatic incurable solid malignancy that has progressed after available standard therap...
What is the current status of trial NCT02410512?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 610 participants. The study started on 2015-04-24. Estimated completion is 2019-11-22.
What conditions does trial NCT02410512 study?
This clinical trial studies the following conditions: Neoplasms.
What interventions are being tested in trial NCT02410512?
The interventions under investigation include: Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 [PD-L1] antibody (DRUG), MOXR0916, a humanized agonist anti-OX40 monoclonal antibody (DRUG).
Who is sponsoring clinical trial NCT02410512?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02410512 being conducted?
This trial has 20 study locations across Arizona, Colorado, Connecticut, District of Columbia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02410512's enrollment target sits among peer trials
610 20th of 158 higher than 138 of 158 other Neoplasms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)
RECRUITING · Phase 1
-
A Study of GSK5764227 in Participants With. Advanced Solid Tumors (EMBOLD PanTumor-101)
RECRUITING · Phase 1
-
Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
RECRUITING · Phase 1
-
Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers
RECRUITING · Phase 1
-
Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03536312 · 610 participants · NA
Treatment in Thoracic Aortic Aneurysm: Surgery vs Surveillance
- NCT07075718 · 610 participants · Phase 2
Phase 2/Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
- NCT00823654 · 609 participants
Serum Biomarkers to Characterize the Effects of Therapy on Ovarian Reserve in Premenopausal Women With Early-stage Breast Cancer or BRCA Mutations
- NCT04224493 · 612 participants · Phase 3
A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI